

Repair effects of leramistat in participants with rheumatoid arthritis

Submission date 30/04/2026	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 01/05/2026	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 01/05/2026	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Prof John Isaacs

Contact details

Newcastle upon Tyne Hospitals NHS Trust
Newcastle upon Tyne
United Kingdom
NE1 4LP
44 (0)191 213 7118
John.Isaacs@newcastle.ac.uk

Type(s)

Public, Scientific

Contact name

Mr Patrick Round

Contact details

3 Pancras Square
London
United Kingdom

N1C 4AG

-

patrick@istesso.co.uk

Additional identifiers

Integrated Research Application System (IRAS)

1012675

Protocol serial number

IST-03

Study information

Scientific Title

A randomised, double-blind, placebo-controlled trial of the effects of leramistat (MBS2320) on muscle in participants with rheumatoid arthritis

Study objectives

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 07/10/2025, East of England - Essex Research Ethics Committee (2 Redman Place, London, EC20 1JQ, United Kingdom; +44 2071048106; approvals@hra.nhs.uk), ref: 25/EE/0186

Primary study design

Interventional

Allocation

Randomized controlled trial

Masking

Blinded (masking used)

Control

Placebo

Assignment

Single

Purpose

Treatment

Study type(s)

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

leramistat

Primary outcome(s)

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Key secondary outcome(s)

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Completion date

09/09/2027

Eligibility

Key inclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

120 years

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Date of first enrolment

20/04/2026

Date of final enrolment

29/01/2027

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

NIHR Newcastle Clinical Research Facility

Level 6 Leazes Wing

Royal Victoria Infirmary

Queen Victoria Road

Newcastle upon Tyne

England

NE1 4LP

Sponsor information

Organisation

Istesso Therapeutics

Funder(s)

Funder type

Industry

Funder Name

Istesso Therapeutics

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available